Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Disparities in Healthcare Affordability Among Childhood Cancer Survivors Persist Following the Affordable Care Act

Mark A. Fiala, BS, Jin Huang, PhD, Mary E. Hartman, MD MPH

Blood (2019) 134 (Supplement_1): 2182.

https://doi.org/10.1182/blood-2019-131105

Published: 2019

Journal Articles

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Shady Adnan Awad, MD, Helena Hohtari, MD, Komal Kumar Javarappa, PhD, Tania Brandstoetter, Daehong Kim, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Soili Kytölä, PhD, Kimmo Porkka, Eszter Doma, PhD, Veronika Sexl, MD PhD, Matti Kankainen, PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 190.

https://doi.org/10.1182/blood-2019-126584

Published: 2019

Journal Articles

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

Chiaki Naito, MD, Hiroaki Shimizu, MD PhD, Yuri Miyazawa, MD PhD, Takuma Ishizaki, MD PhD, Akihiko Yokohama, MD PhD, Takayuki Saito, MD PhDProf, Norifumi Tsukamoto, MD PhD, Hiroshi Handa, MD PhD

Blood (2019) 134 (Supplement_1): 5434.

https://doi.org/10.1182/blood-2019-127956

Published: 2019

Journal Articles

Survival Outcome and Insurance Status Among Hodgkin's Lymphoma (HL) Patients: Data from SEER 2007-2014

Qian Wang, MD MPH, Changchuan Jiang, MDMPH, Yaning Zhang, MD, Stuthi Perimbeti, MD MPH, Prateeth Pati, MD, Lawrence Cytryn, MD

Blood (2017) 130 (Supplement 1): 915.

https://doi.org/10.1182/blood.V130.Suppl_1.915.915

Published: 2017

Journal Articles

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)

Hiroaki Shimizu, MD PhD, Satoru Takada, MD, Nahoko Hatsumi, MD, Akihiko Yokohama, MD PhD, Takayuki Saitoh, MD PhDProf, Toru Sakura, PhD MD, Hiroshi Handa, MD PhDChief Division

Blood (2017) 130 (Supplement 1): 2716.

https://doi.org/10.1182/blood.V130.Suppl_1.2716.2716

Published: 2017

Journal Articles

Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA)

Andrea Sitlinger, MD, Rishi Sachdev, David Anderson, BS/MS, S. Yousuf Zafar, MD MHS

Blood (2017) 130 (Supplement 1): 4680.

https://doi.org/10.1182/blood.V130.Suppl_1.4680.4680

Published: 2017

Journal Articles

Population Level Survival for Patients with Multiple Myeloma By Insurance Type and Early Indications of Changes with Adoption of the Medicaid Expansion of the Affordable Care Act

Dianne Pulte, MD, Lina Jansen, PhD, Janick Weberpals, Hermann Brenner, MD MPH

Blood (2017) 130 (Supplement 1): 3438.

https://doi.org/10.1182/blood.V130.Suppl_1.3438.3438

Published: 2017

Journal Articles

Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalitions (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group

Blood (2016) 128 (22): 1602.

https://doi.org/10.1182/blood.V128.22.1602.1602

Published: 2016

Journal Articles

The Affordable Care Act Improves Healthcare Access and Utilization Among Young Adults with Sickle Cell Disease

Wendy Darlington, MD MAPP, Sydeaka P Watson, PhD, Tara O Henderson, MD MPH, John M Cunningham, MD, Rena M Conti, PhD

Blood (2016) 128 (22): 4747.

https://doi.org/10.1182/blood.V128.22.4747.4747

Published: 2016

Journal Articles

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Wei Wang, Jorge E. Cortes, Guilin Tang, Joseph D. Khoury, Sa Wang, Carlos E. Bueso-Ramos, Joseph A. DiGiuseppe, Zi Chen, Hagop M. Kantarjian, L. Jeffrey Medeiros, Shimin Hu

Blood (2016) 127 (22): 2742–2750.

https://doi.org/10.1182/blood-2016-01-690230

Published: 2016

Includes: Supplemental data

Journal Articles

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Christian T. Dietz, PhD, Alice Charlotte Fabarius, PhD, Michael Lauseker, PhD, Susanne Saussele, Lida Kalmanti, Sébastien Rinaldetti, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martine Jotterand, Alois Gratwohl, Axel R. Zander, Professor, Nicolaus Kröger, Dietrich W. Beelen, MD, Jürgen Novotny, Christoph Nerl, Christof Scheid, MD PhD, Karsten Spiekermann, Jiri Mayer, MD, Herbert G. Sayer, Christiane Falge, Donald Bunjes, MD, Hartmut Döhner, Prof. Dr., Arnold Ganser, Peter Brossart, MD, Rainer Schwerdtfeger, Herrad Baumann, Rolf Kuse, Hans Walter Lindemann, MD, Matthias Bormann, Bernd Hertenstein, MD, Gabriela M. Baerlocher, Carlo Aul, MD, Peter Staib, Matthias Edinger, MD, Michael Schatz, Axel A Fauser, Renate Arnold, MD, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, Susanne Schnittger, PhD, Martin C. Müller, MD, Andreas Reiter, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Joerg Hasford, Michele Baccarani, Ruediger Hehlmann, MD

Blood (2015) 126 (23): 1581.

https://doi.org/10.1182/blood.V126.23.1581.1581

Published: 2015

Journal Articles

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Acute Myeloid Leukemia (AML) Patients

Hiroaki Shimizu, MDPhD, Akihiko Yokohama, MD PhD, Nahoko Hatsumi, MD, Satoru Takada, MD, Takayuki Saitoh, MD, PhD, Hiroshi Handa, MD, Toru Sakura, MD PhD, Yoshihisa Nojima, MD PhD

Blood (2014) 124 (21): 3673.

https://doi.org/10.1182/blood.V124.21.3673.3673

Published: 2014

Journal Articles

Characterization and Quantification Of Rare BCR-ABL1 Fusion Transcripts

Susanne Schnittger, PhD, Frank Dicker, PhD, Tamara Alpermann, Christiane Eder, PhD, Annette Fasan, PhD, Simone Weber, Sabine Jeromin, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 4013.

https://doi.org/10.1182/blood.V122.21.4013.4013

Published: 2013

Journal Articles

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Nemoto, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 2939.

https://doi.org/10.1182/blood.V120.21.2939.2939

Published: 2012

Journal Articles

Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Blood (2012) 120 (10): 2098–2108.

https://doi.org/10.1182/blood-2012-01-407601

Published: 2012

Includes: Supplemental data

Journal Articles

Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

Blood (2011) 118 (21): 782.

https://doi.org/10.1182/blood.V118.21.782.782

Published: 2011

Journal Articles

Common Recurrent DKC1 Mutation A353V Does Not Support Telomere Maintenance in Induced Pluripotent Stem Cells

Baiwei Gu, Ph.D, Jason A. Mills, PhD, Jian-meng Fan, B.S, Deborah L. French, PhD, Monica Bessler, MD, PhD, Philip Mason, PhD

Blood (2011) 118 (21): 50.

https://doi.org/10.1182/blood.V118.21.50.50

Published: 2011

Journal Articles

Identification of Modifiable Factors Associated with Lower Adherence to Preventive Care Practices In HCT Survivors.

Nandita Khera, MD, Eric J. Chow, MD, MPH, Wendy Leisenring, ScD, Karen L Syrjala, PhD, K. Scott Baker, MD, MS, Mary E.D. Flowers, MD, Paul J. Martin, MD, Stephanie J. Lee, MD, MPH

Blood (2010) 116 (21): 3818.

https://doi.org/10.1182/blood.V116.21.3818.3818

Published: 2010

Journal Articles

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Delphine Rea, MD, PhD, Gabriel Etienne, MD, Franck Emmanuel Nicolini, MD, PhD, Pascale Cony-Makhoul, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD, Francoise Huguet, MD, Michel Tulliez, MD, Martine Gardembas, MD, Krimo Bouabdallah, MD, Philippe Rousselot, MD, PhD, Jean-Michel Cayuela, PhD, Herve Dombret, MD, PhD, François-Xavier Mahon, MD, PhD

Blood (2009) 114 (22): 3288.

https://doi.org/10.1182/blood.V114.22.3288.3288

Published: 2009

Journal Articles

Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.

Blood (2008) 112 (11): 1649.

https://doi.org/10.1182/blood.V112.11.1649.1649

Published: 2008

NARROW

Disparities in Healthcare Affordability Among Childhood Cancer Survivors Persist Following the Affordable Care Act

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

Survival Outcome and Insurance Status Among Hodgkin's Lymphoma (HL) Patients: Data from SEER 2007-2014

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)

Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA)

Population Level Survival for Patients with Multiple Myeloma By Insurance Type and Early Indications of Changes with Adoption of the Medicaid Expansion of the Affordable Care Act

Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalitions (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group

The Affordable Care Act Improves Healthcare Access and Utilization Among Young Adults with Sickle Cell Disease

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Acute Myeloid Leukemia (AML) Patients

Characterization and Quantification Of Rare BCR-ABL1 Fusion Transcripts

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

Common Recurrent DKC1 Mutation A353V Does Not Support Telomere Maintenance in Induced Pluripotent Stem Cells

Identification of Modifiable Factors Associated with Lower Adherence to Preventive Care Practices In HCT Survivors.

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only